The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease: An emerging field
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Coronary heart disease and stroke, the deadliest forms of cardiovascular disease (CVD), are mainly caused by atherosclerosis, a chronic inflammatory disease of the artery wall driven by maladaptive immune responses in the vessel wall. Various risk factors for CVD influence this pathogenic process, including diabetes mellitus, hypertension, dyslipidaemia, and obesity. Indoleamine 2,3-dioxygenase (IDO), an enzyme catalyzing the rate-limiting step in the kynurenine pathway of tryptophan degradation, is strongly induced by inflammation in several tissues, including the artery wall. An increasing body of evidence indicates that IDO promotes immune tolerance, decreases inflammation, and functions as a homeostatic mechanism against excessive immune reactions. This review provides an overview of the emerging field of the kynurenine pathway of tryptophan degradation in CVD, emphasizing the role of IDO-mediated tryptophan metabolism and its metabolites in the modulation of ‘classical’ cardiovascular risk factors, such as hypertension, obesity, lipid metabolism, diabetes mellitus, and in the development of atherosclerotic CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Kynurenic acid antagonists and kynurenine pathway inhibitors
Stone, T. W. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.633 · Cited by 79
Research works printed but not linked: 93
- 10.2174/1381612811319330003 · DOI
- 10.1160/TH11-05-0321 · DOI
- 10.1084/jem.20092243 · DOI · Paper page
- 10.1016/j.imbio.2011.06.006 · DOI
- 10.1093/cvr/cvt033 · DOI · Paper page
- 10.4049/jimmunol.170.12.5809 · DOI · Paper page
- 10.1016/S0165-5728(02)00176-5 · DOI · Paper page
- 10.1186/ar2205 · DOI
- 10.1016/j.jaci.2007.11.021 · DOI
- 10.1053/j.gastro.2003.08.031 · DOI · Paper page
- 10.1016/S0021-9150(99)00011-8 · DOI · Paper page
- 10.1128/IAI.70.7.3959-3961.2002 · DOI · Paper page
- 10.1046/j.1440-1711.2003.t01-1-01177.x · DOI · Paper page
- 10.1515/bchm2.1936.243.6.237 · DOI
- Yamamoto, 1967, J Biol Chem, 242, 5260, 10.1016/S0021-9258(18)99420-2 · DOI · Paper page
- Werner-Felmayer, 1990, Cancer Res, 50, 2863
- 10.1016/j.coph.2003.10.006 · DOI · Paper page
- 10.1254/jjp.71.183 · DOI · Paper page
- Parsons, 1997, J Pharmacol Exp Thera, 283, 1264, 10.1016/S0022-3565(24)37160-5 · DOI · Paper page
- Hilmas, 2001, J Neurosci, 21, 7463, 10.1523/JNEUROSCI.21-19-07463.2001 · DOI · Paper page
- 10.1093/schbul/sbq002 · DOI · Paper page
- 10.1016/S0304-3940(01)02242-X · DOI · Paper page
- 10.1111/j.1471-4159.1991.tb03460.x · DOI · Paper page
- 10.1038/nrd870 · DOI · Paper page
- 10.1126/science.281.5380.1191 · DOI · Paper page
- 10.1084/jem.189.9.1363 · DOI · Paper page
- 10.1046/j.1365-2567.2002.01526.x · DOI · Paper page
- 10.1016/j.immuni.2005.03.013 · DOI · Paper page
- 10.1172/JCI200421583 · doi:10.1172/jci200421583 · Paper page
- 10.1084/jem.20020052 · DOI · Paper page
- 10.1038/sj.cdd.4401073 · DOI · Paper page
- 10.1165/rcmb.2011-0438OC · DOI
- 10.1002/jcb.21384 · DOI
- 10.1016/j.imlet.2010.05.008 · DOI
- 10.4049/jimmunol.0903670 · DOI · Paper page
- 10.1038/ni.2077 · DOI · Paper page
- 10.1038/nm.2092 · DOI · Paper page
- Changsirivathanathamrong, 2011, Crit Care Med, 39, 2678, 10.1097/CCM.0b013e31822827f2 · DOI
- 10.1081/CEH-100106826 · doi:10.1081/ceh-100106826
- 10.1161/01.HYP.35.1.413 · DOI
- 10.1074/jbc.C200303200 · DOI
- 10.1111/j.1440-1681.1994.tb02460.x · DOI
- 10.1291/hypres.25.135 · DOI
- 10.1172/JCI200319451 · DOI · Paper page
- 10.1080/00365510802245685 · DOI · Paper page
- 10.1111/j.1365-2249.2007.03325.x · DOI · Paper page
- 10.1002/oby.20491 · DOI · Paper page
- 10.1152/ajpregu.00373.2011 · DOI · Paper page
- 10.1371/journal.pone.0073404 · DOI
- 10.1016/j.cmet.2012.04.001 · DOI · Paper page
- 10.1093/eurheartj/ehs175 · DOI · Paper page
- 10.4161/cbt.12.12.18142 · DOI
- Oxenkrug, 2013, Hepat Res Treat, 2013, 149247
- 10.3109/13813455.2011.623705 · DOI
- Hattori, 1984, Acta Vitaminol Enzymol, 6, 221
- 10.1007/BF02355886 · DOI
- 10.1074/jbc.M109.087338 · DOI · Paper page
- Kotake, 1975, Acta Vitaminol Enzymol, 29, 236
- 10.1166/ajnn.2011.1024 · DOI
- 10.3945/ajcn.2009.28571 · DOI
- 10.1007/s12035-013-8497-4 · DOI · Paper page
- 10.4049/jimmunol.0901577 · DOI
- Okamoto, 1983, Princess Takamatsu Symp, 13, 297
- 10.2337/diabetes.51.2.356 · DOI · Paper page
- 10.1038/ni846 · DOI · Paper page
- 10.1371/journal.pone.0071044 · DOI
- 10.2337/db06-0617 · DOI · Paper page
- 10.1016/j.ijcard.2012.12.090 · DOI
- 10.1161/ATVBAHA.110.219329 · DOI · Paper page
- 10.1046/j.1365-2362.2003.01186.x · DOI · Paper page
- 10.1111/j.1542-4758.2010.00464.x · DOI
- 10.1161/CIRCULATIONAHA.106.666511 · DOI
- 10.1016/j.atherosclerosis.2008.08.014 · DOI
- 10.1016/j.clinbiochem.2010.06.008 · doi:10.1016/j.clinbiochem.2010.06.008
- 10.2478/v10039-010-0015-6 · DOI
- 10.1016/j.atherosclerosis.2008.10.002 · DOI
- 10.3109/07853890903321559 · DOI
- 10.4049/jimmunol.179.8.5246 · DOI · Paper page
- 10.1161/ATVBAHA.111.229443 · DOI · Paper page
- 10.1161/CIRCRESAHA.111.256529 · DOI
- 10.1172/JCI117211 · DOI
- 10.1016/j.atherosclerosis.2005.09.010 · DOI
- 10.1007/s11064-010-0187-2 · DOI
- 10.1111/j.1460-9568.2007.05838.x · DOI · Paper page
- 10.1186/1742-2094-8-17 · DOI · Paper page
- 10.1007/s00210-011-0611-4 · DOI
- 10.1016/S0165-6147(00)01451-6 · DOI · Paper page
- 10.1016/j.ejphar.2011.05.069 · DOI
- 10.1038/jcbfm.1992.57 · DOI · Paper page
- 10.1016/j.nbd.2008.07.013 · DOI
- 10.1016/j.ejphar.2007.02.029 · DOI
- Moroni F, Cozzi A, Peruginelli F et al. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv Exp Med Biol 1999; 467: 199-206. E · DOI
- 10.1016/j.neuroscience.2013.04.063 · DOI
Cited by
Adaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Self-citationTrace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)
Seok, S.-H., Ma, Z.-X., Feltenberger, J. B., Chen, H., Chen, H., Scarlett, C., Lin, Z., Satyshur, K. A., Cortopassi, M., Jefcoate, C. R., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000631 · Cited by 157
Moffett, J. R., Arun, P., Puthillathu, N., Vengilote, R., Ives, J. A., Badawy, A. A.-B., & Namboodiri, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00031 · Cited by 89
“The kynurenine metabolite 3hydroxyanthranilate has been found to affect foam cell formation by reducing uptake of oxidized low-density lipoprotein by macrophages (71, 72).”
BackgroundHormones, Metabolism and the Benefits of Exercise
(2017) · Research and Perspectives in Endocrine Interactions · doi:10.1007/978-3-319-72790-5 · Cited by 44
Navrotskaya, V., Oxenkrug, G., Vorobyova, L., & Summergrad, P. (2015) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000120 · Cited by 14
Metadata
- Authors
- Polyzos, K. A., & Ketelhuth, D. F. J.
- Venue
- Hämostaseologie
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015
- Volume
- 35
- Issue
- 02
- Pages
- 128-136
- ISSN
- 0720-9355 (ISSN-L)
- 2567-5761
- OpenAlex
- W2135674854
- Cited by
- 94
- References
- 7
- FWCI
- 2.52
- Type
- journal article
- Language
- de
- Open access
- closed
- Funders
- Swedish Heart-Lung Foundation
- Karolinska Institute Cardiovascular Program Career Development
- Åke Wibergs Stiftelse
- Stiftelsen för Gamla Tjänarinnor
- Stiftelsen Professor Nanna Svartz fond
- KI fond
- Alexander S. Onassis Public Benefit Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease: An emerging field. https://app.cochat.ai/papers/10.5482/hamo-14-10-0052
- The paper
- Polyzos, K. A., & Ketelhuth, D. F. J. (2015). The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease: An emerging field. Hämostaseologie. https://doi.org/10.5482/hamo-14-10-0052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.